ARMK just posted its strongest week in months, and the Street is rushing to keep pace.
The stock closed Tuesday at $48.41, up nearly 9% on the day and 7% on the week. The catalyst was a fiscal Q2 earnings release that cleared the bar — and then some. Analysts from Morgan Stanley, JP Morgan, Truist, UBS, Stifel, and Baird all raised price targets on Wednesday morning. The consensus now points toward the low-to-mid $50s, well above last week's trading range.
The analyst reaction has been uniformly constructive. JP Morgan lifted its target from $49 to $55, maintaining Overweight. Truist and Baird both moved to $58, reiterating Buy and Outperform respectively. UBS raised from $48 to $56, keeping Buy. Even Morgan Stanley, the relative bear in the room with an Equal-Weight rating, bumped from $45 to $50 — the first time its target has cleared the stock's current price in some time. The mean target now sits around $51.94, implying modest further upside from current levels. The bulls' case rests on ARMK's high retention rates, recent contract wins, and a credible path to high single-digit organic revenue growth in FY26. The bears counter with cost pressures — labour and food inflation — plus elevated leverage and sensitivity to consumer spending trends.
The positioning story is less charged than the price action might suggest. Short interest has fallen about 12% over the past week, dropping to roughly 3.7% of the free float — a level that signals some short covering in the wake of the print, but nothing that reads as a squeeze. The ORTEX short score of 36.5 sits comfortably below the midpoint of the 0-100 range, and availability in the lending market remains ample. Cost to borrow has doubled over the week to 0.64%, technically its highest level in recent months, but the absolute figure is still well below anything that would constrain a new short position. Borrowing ARMK remains cheap.
Where the positioning data does light up is in options. The put/call ratio jumped to 0.34 on Tuesday — nearly four standard deviations above its 20-day average of 0.10. That reading is striking against the backdrop of a stock that had just rallied hard: with calls already in the money, some of the put activity likely reflects holders locking in gains or hedging the post-earnings pop rather than outright directional bearishness. The prior earnings event on May 5 saw the stock gain 2.2% on the day and 8.1% over the subsequent five sessions, suggesting the market had been warming to the name before this latest print.
Institutionally, the register looks well-anchored. Capital Research, Vanguard, and BlackRock collectively hold roughly 27% of shares. BlackRock added around 478,000 shares as of April 30, while Capital Research added 334,000 over the same period — quiet accumulation rather than anything dramatic. EV/EBITDA has crept up to approximately 11x over the past month, reflecting the re-rating, though the forward earnings yield at roughly 4.9% and the company's 94th-percentile rank on forward EPS growth paint a picture of a business that still has room to grow into its multiple.
The key question after a near-9% single-day move: whether the revised analyst targets in the $54–$58 range hold as a near-term ceiling, or whether the organic growth acceleration the company has signalled — and the Street is now pricing in — proves durable enough to reopen the valuation debate.
See the live data behind this article on ORTEX.
Open ARMK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
